                         SEQUENCE LISTING

<110>  Universit de Genve
       Les Hpitaux Universitaires de Genve
 
<120>  New cell penetrating peptides

<130>  P1584PC00

<150>  US 61/700,432
<151>  2012-09-13

<150>  EP 12184311.4
<151>  2012-09-13

<160>  23    

<170>  PatentIn version 3.5

<210>  1
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCP1

<400>  1

Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys Ser Arg Ala Lys Phe 
1               5                   10                  15      


Lys 
    


<210>  2
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP2

<400>  2

Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys Ser Arg Ala Lys Phe 
1               5                   10                  15      


Lys Gln Leu Leu Gln His Tyr Arg Glu Val Ala Ala Ala Lys 
            20                  25                  30  


<210>  3
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ovalbumine CD8 epitope

<400>  3

Ser Ile Ile Asn Phe Glu Lys Leu 
1               5               


<210>  4
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP1-OVA fusion polypeptide

<400>  4

Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys Ser Arg Ala Lys Phe 
1               5                   10                  15      


Lys Glu Gln Leu Glu Ser Ile Ile Asn Phe Glu Lys Leu Thr Glu Trp 
            20                  25                  30          


Thr 
    


<210>  5
<211>  46
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP2-OVA fusion polypeptide

<400>  5

Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys Ser Arg Ala Lys Phe 
1               5                   10                  15      


Lys Gln Leu Leu Gln His Tyr Arg Glu Val Ala Ala Ala Lys Glu Gln 
            20                  25                  30          


Leu Glu Ser Ile Ile Asn Phe Glu Lys Leu Thr Glu Trp Thr 
        35                  40                  45      


<210>  6
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Generic sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is K, R, or H

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is R, K, or H

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is Y, W, or F

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is K, R, or H

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is N or Q

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is R, K, or H

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is V, I, M, L, F, or A

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is A, V, L, I, or G

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is S or T

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is R, K, or H

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is K, R, or H

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa is R, K, or H

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa is A, V, L, I, or G

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Xaa is K, R, or H

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is F, L, V, I, Y, W, or M

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is K, R, or H

<400>  6

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa 
    


<210>  7
<211>  17
<212>  PRT
<213>  artificial sequence

<220>
<223>  Generic sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is K or R

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is R or K

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is Y, W, or F

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is K or R

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is N or Q

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is R or K

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is V, I, M or L

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is A or G

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is S or T

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is R or K

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is K or R

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa is R or K

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa is A or G

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Xaa is K or R

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is F, Y, or W

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is K or R

<400>  7

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa 
    


<210>  8
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  CPP8

<400>  8

Gln His Tyr Arg Glu Val Ala Ala Ala Lys Ser Ser Glu Asn Asp 
1               5                   10                  15  


<210>  9
<211>  19
<212>  PRT
<213>  artificial sequence

<220>
<223>  CPP10

<400>  9

Arg Glu Val Ala Ala Ala Lys Ser Ser Glu Asn Asp Arg Leu Arg Leu 
1               5                   10                  15      


Leu Leu Lys 
            


<210>  10
<211>  25
<212>  PRT
<213>  artificial sequence

<220>
<223>  CPP11

<400>  10

Gln Leu Leu Gln His Tyr Arg Glu Val Ala Ala Ala Lys Ser Ser Glu 
1               5                   10                  15      


Asn Asp Arg Leu Arg Leu Leu Leu Lys 
            20                  25  


<210>  11
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  spacer

<400>  11

Glu Gln Leu Glu 
1               


<210>  12
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  spacer

<400>  12

Thr Glu Trp Thr 
1               


<210>  13
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  fragment of Zebra

<400>  13

Leu Glu Ile Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys Cys Arg 
1               5                   10                  15      


Ala Lys Phe Lys Gln 
            20      


<210>  14
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  fragment of Zebra

<400>  14

Ser Glu Leu Glu Ile Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys 
1               5                   10                  15      


Cys Arg Ala Lys Phe 
            20      


<210>  15
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Enterokinase target site

<400>  15

Asp Asp Asp Lys 
1               


<210>  16
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Factor Xa target site

<400>  16

Ile Glu Asp Gly Arg 
1               5   


<210>  17
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Thrombin target site

<400>  17

Leu Val Pro Arg Gly Ser 
1               5       


<210>  18
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Protease TEV target site

<400>  18

Glu Asn Leu Tyr Phe Gln Gly 
1               5           


<210>  19
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PreScission protease target site

<400>  19

Leu Glu Val Leu Phe Gln Gly Pro 
1               5               


<210>  20
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Furin target site


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is any amino acid

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is R or K

<400>  20

Arg Xaa Xaa Arg 
1               


<210>  21
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP6

<400>  21

Lys Arg Tyr Lys Asn Arg Val Ala 
1               5               


<210>  22
<211>  42
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP14

<400>  22

Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys Cys Arg Ala Lys Phe 
1               5                   10                  15      


Lys Gln Leu Leu Gln His Tyr Arg Glu Val Ala Ala Ala Lys Ser Ser 
            20                  25                  30          


Glu Asn Asp Arg Leu Arg Leu Leu Leu Lys 
        35                  40          


<210>  23
<211>  245
<212>  PRT
<213>  Epstein-Barr virus

<400>  23

Met Met Asp Pro Asn Ser Thr Ser Glu Asp Val Lys Phe Thr Pro Asp 
1               5                   10                  15      


Pro Tyr Gln Val Pro Phe Val Gln Ala Phe Asp Gln Ala Thr Arg Val 
            20                  25                  30          


Tyr Gln Asp Leu Gly Gly Pro Ser Gln Ala Pro Leu Pro Cys Val Leu 
        35                  40                  45              


Trp Pro Val Leu Pro Glu Pro Leu Pro Gln Gly Gln Leu Thr Ala Tyr 
    50                  55                  60                  


His Val Ser Thr Ala Pro Thr Gly Ser Trp Phe Ser Ala Pro Gln Pro 
65                  70                  75                  80  


Ala Pro Glu Asn Ala Tyr Gln Ala Tyr Ala Ala Pro Gln Leu Phe Pro 
                85                  90                  95      


Val Ser Asp Ile Thr Gln Asn Gln Gln Thr Asn Gln Ala Gly Gly Glu 
            100                 105                 110         


Ala Pro Gln Pro Gly Asp Asn Ser Thr Val Gln Thr Ala Ala Ala Val 
        115                 120                 125             


Val Phe Ala Cys Pro Gly Ala Asn Gln Gly Gln Gln Leu Ala Asp Ile 
    130                 135                 140                 


Gly Val Pro Gln Pro Ala Pro Val Ala Ala Pro Ala Arg Arg Thr Arg 
145                 150                 155                 160 


Lys Pro Gln Gln Pro Glu Ser Leu Glu Glu Cys Asp Ser Glu Leu Glu 
                165                 170                 175     


Ile Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys Cys Arg Ala Lys 
            180                 185                 190         


Phe Lys Gln Leu Leu Gln His Tyr Arg Glu Val Ala Ala Ala Lys Ser 
        195                 200                 205             


Ser Glu Asn Asp Arg Leu Arg Leu Leu Leu Lys Gln Met Cys Pro Ser 
    210                 215                 220                 


Leu Asp Val Asp Ser Ile Ile Pro Arg Thr Pro Asp Val Leu His Glu 
225                 230                 235                 240 


Asp Leu Leu Asn Phe 
                245 


